Sandoz affirms its generic anti-clotting drug will be approved
BASEL, Switzerland Sandoz is “confident” that it will win approval for a generic anti-clotting drug, according to published reports.
Reuters reported that Sandoz, the generics arm of Novartis, and partner Momenta Pharmaceuticals were hoping to gain approval of a generic version of Sanofi-Aventis’s Lovenox (enoxaparin), but that Sandoz CEO Jeff George was “cautiously optimistic.”
Teva and a partnership involving Watson Pharmaceuticals and Amphastar Pharmaceuticals are seeking approval for versions of the drug as well, according to Reuters. The drug is used to treat deep vein thrombosis.